Teriflunomide in treatment of remitting-relapsing multiple sclerosis: efficacy and safety
The review presents the data concerning the mechanism of action, pharmacokinetics and results of clinical researches of teriflunomide. Teriflunimide is a new anti-inflammatory and immunomodulatory oral drug for pathogenic treatment of multiple sclerosis. Efficacy of teriflunomide in the treatment of relapsing forms of multiple sclerosis was shown in phase II and III clinical studies. It was proved that the drug significantly decreases the relapse rate and sustained disability progression in relapsing forms of multiple sclerosis and has a favorable profile of safety and tolerabilty.